A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Fazpilodemab (Primary) ; Fazpilodemab (Primary)
- Indications Insulin resistance
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Preliminary results (n=71) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 03 May 2017 Status changed from recruiting to completed.